Corentin Orvain
Overview
Explore the profile of Corentin Orvain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bertoli S, Berard E, Peterlin P, Guieze R, Desbrosses Y, Hicheri Y, et al.
Haematologica
. 2025 Feb;
PMID: 39911128
Not available.
2.
3.
Vo P, Sandmaier B, Othus M, Ali N, Rodriguez-Arboli E, Orvain C, et al.
Bone Marrow Transplant
. 2025 Jan;
PMID: 39881206
Methodological advancements now allow older adults with AML to receive allografts although conflicting data exist regarding relative outcomes across age groups and benefits of different conditioning intensities. We retrospectively analyzed...
4.
Mosnier C, Bellal S, Cottin L, Boyer-Perrard F, Boyer F, Lemoine S, et al.
Blood Adv
. 2025 Jan;
9(6):1303-1311.
PMID: 39820709
Patients with essential thrombocythemia (ET) have a chronic evolution with a risk of hematologic transformation associated with a dismal outcome. Because patients with resistance or intolerance have adverse prognosis, it...
5.
Orvain C, Milano F, Rodriguez-Arboli E, Othus M, Petersdorf E, Sandmaier B, et al.
Leukemia
. 2024 Dec;
39(2):381-390.
PMID: 39668236
Lack of HLA-matched related/unrelated donor remains a barrier to allogeneic hematopoietic cell transplantation (HCT) for adult acute myeloid leukemia (AML), with ongoing uncertainty about optimal donor type if more than...
6.
Vo P, Sandmaier B, Othus M, Ali N, Rodriguez-Arboli E, Orvain C, et al.
Res Sq
. 2024 Nov;
PMID: 39606437
Methodological advancements now allow older adults with AML to receive allografts although conflicting data exist regarding relative outcomes across age groups and benefits of different conditioning intensities. We retrospectively analyzed...
7.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Salit R, et al.
Blood Adv
. 2024 Nov;
9(4):797-807.
PMID: 39561372
The aim of our study was to analyze the potential survival benefit associated with hematopoietic stem cell transplantation (HSCT) according to clinicobiological scores, which incorporate mutation-enhanced international prognostic score system...
8.
Ali N, Othus M, Rodriguez-Arboli E, Orvain C, Milano F, Sandmaier B, et al.
Blood Adv
. 2024 Oct;
9(3):558-570.
PMID: 39374582
Measurable residual disease (MRD) by multiparametric flow cytometry (MFC) before allogeneic hematopoietic cell transplantation (HCT) identifies patients at high risk of acute myeloid leukemia (AML) relapse, often occurring early after...
9.
Othus M, Baccon D, Ali N, Rodriguez-Arboli E, Orvain C, Milano F, et al.
Bone Marrow Transplant
. 2024 Aug;
59(12):1667-1675.
PMID: 39210036
Outcomes of adults with AML after allografting vary widely. While numerous covariates have been associated with relapse, non-relapse mortality (NRM), and/or shorter survival, the impact of incomplete blood count recovery...
10.
Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas P, Iat A, et al.
Leukemia
. 2024 Jul;
38(9):1949-1957.
PMID: 39020060
Patients with Core-Binding Factor (CBF) and NPM1-mutated acute myeloid leukemia (AML) can be monitored by quantitative PCR after having achieved first complete remission (CR) to detect morphologic relapse and drive...